# Step 10: ç—‡ä¾‹æç¤º(Case Presentation)ã®åŸ·ç­†

### ğŸ“‹ ã“ã®ã‚¹ãƒ†ãƒƒãƒ—ã®ç›®çš„

è«–æ–‡ã®æ ¸å¿ƒéƒ¨åˆ†ã§ã‚ã‚‹ç—‡ä¾‹æç¤ºï¼ˆCase Presentation / Case Reportï¼‰ã‚’åŸ·ç­†ã—ã¾ã™ã€‚
ã“ã“ã§ã¯ã€å®¢è¦³çš„ãªäº‹å®Ÿã®ã¿ã‚’ã€æ™‚é–“çµŒéã«æ²¿ã£ã¦æ­£ç¢ºã‹ã¤ç°¡æ½”ã«è¨˜è¿°ã™ã‚‹ã“ã¨ãŒæ±‚ã‚ã‚‰ã‚Œã¾ã™ã€‚
èª­è€…ãŒã¾ã‚‹ã§ãã®æ‚£è€…ã‚’è¿½ä½“é¨“ã—ã¦ã„ã‚‹ã‹ã®ã‚ˆã†ã«ã€è‡¨åºŠçµŒéã‚’åˆ†ã‹ã‚Šã‚„ã™ãæç¤ºã™ã‚‹æŠ€è¡“ã‚’å­¦ã³ã¾ã™ã€‚

![ç—‡ä¾‹æç¤ºã®åŸ·ç­†](https://files.manuscdn.com/user_upload_by_module/session_file/90346460/tKBqDfbAmxUWdICY.png)

### â±ï¸ æ‰€è¦æ™‚é–“

2ã€œ4æ™‚é–“

### ğŸ¯ é”æˆåŸºæº–

- æ‚£è€…ã®ãƒ—ãƒ©ã‚¤ãƒã‚·ãƒ¼ã«é…æ…®ã—ã€åŒ¿ååŒ–ã•ã‚ŒãŸæƒ…å ±ã®ã¿ãŒè¨˜è¿°ã•ã‚Œã¦ã„ã‚‹ã€‚
- è‡¨åºŠçµŒéãŒã€åˆè¨ºâ†’å…¥é™¢â†’æ¤œæŸ»â†’æ²»ç™‚â†’è»¢å¸°ã€ã¨ã„ã†æ™‚ç³»åˆ—ã«æ²¿ã£ã¦è«–ç†çš„ã«è¨˜è¿°ã•ã‚Œã¦ã„ã‚‹ã€‚
- è¨ºå¯Ÿæ‰€è¦‹ã€æ¤œæŸ»ãƒ‡ãƒ¼ã‚¿ã€ç”»åƒæ‰€è¦‹ãªã©ã®å®¢è¦³çš„ãªäº‹å®Ÿã®ã¿ãŒè¨˜è¿°ã•ã‚Œã€ç­†è€…ã®è§£é‡ˆã‚„è€ƒå¯ŸãŒå«ã¾ã‚Œã¦ã„ãªã„ã€‚
- CAREã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ã®ä¸»è¦é …ç›®ãŒç¶²ç¾…ã•ã‚Œã¦ã„ã‚‹ã€‚

### ğŸ“ è©³ç´°æ‰‹é †

![ç—‡ä¾‹æç¤ºã®åŸ·ç­†](./case_presentation_writing.png)

ç—‡ä¾‹æç¤ºã¯ã€é€šå¸¸ã€ä»¥ä¸‹ã®æ§‹æˆã§è¨˜è¿°ã—ã¾ã™ã€‚
Step 5ã§ä½œæˆã—ãŸã€Œç—‡ä¾‹ãƒ‡ãƒ¼ã‚¿ã®ã‚µãƒãƒªãƒ¼ã€ãŒã€ã“ã®ã‚»ã‚¯ã‚·ãƒ§ãƒ³ã®éª¨å­ã¨ãªã‚Šã¾ã™ã€‚

#### æ‰‹é †1: æ‚£è€…èƒŒæ™¯ã¨ä¸»è¨´

- ã€ŒA 45-year-old man was admitted to our hospital with a 2-week history of non-productive cough and exertional dyspnea.ï¼ˆ45æ­³ç”·æ€§ã€‚2é€±å‰ã‹ã‚‰ã®ä¹¾æ€§å’³å—½ã¨åŠ´ä½œæ™‚å‘¼å¸å›°é›£ã‚’ä¸»è¨´ã«å½“é™¢ã¸å…¥é™¢ã—ãŸã€‚ï¼‰ã€ã®ã‚ˆã†ã«ã€å¹´é½¢ã€æ€§åˆ¥ã€ä¸»è¨´ã€ç—‡çŠ¶ã®æœŸé–“ã‚’è¨˜è¿°ã—ã¾ã™ã€‚
- æ—¢å¾€æ­´ã€ç”Ÿæ´»æ­´ï¼ˆç‰¹ã«å–«ç…™æ­´ï¼‰ã€å®¶æ—æ­´ãªã©ã€æœ¬ç—‡ä¾‹ã«é–¢é€£ã™ã‚‹é‡è¦ãªæƒ…å ±ã‚‚ã“ã“ã«å«ã‚ã¾ã™ã€‚

#### æ‰‹é †2: å…¥é™¢æ™‚ç¾ç—‡ã¨æ¤œæŸ»æ‰€è¦‹

- èº«ä½“æ‰€è¦‹: èº«é•·ã€ä½“é‡ã€ãƒã‚¤ã‚¿ãƒ«ã‚µã‚¤ãƒ³ã€ãŠã‚ˆã³ç‰¹ç•°çš„ãªèº«ä½“æ‰€è¦‹ã‚’è¨˜è¿°ã—ã¾ã™ã€‚
- æ¤œæŸ»æ‰€è¦‹: è¡€æ¶²æ¤œæŸ»ã€å°¿æ¤œæŸ»ã€é«„æ¶²æ¤œæŸ»ãªã©ã®çµæœã‚’è¨˜è¿°ã—ã¾ã™ã€‚
æ­£å¸¸å€¤ã‹ã‚‰é€¸è„±ã—ãŸé‡è¦ãªãƒ‡ãƒ¼ã‚¿ã®ã¿ã‚’æŠœç²‹ã—ã€åŸºæº–å€¤ã‚‚ä½µè¨˜ã™ã‚‹ã®ãŒè¦ªåˆ‡ã§ã™ã€‚
å¤šãã®ãƒ‡ãƒ¼ã‚¿ã‚’ç¾…åˆ—ã™ã‚‹ã‚ˆã‚Šã€Tableã«ã¾ã¨ã‚ã‚‹æ–¹ãŒåˆ†ã‹ã‚Šã‚„ã™ã„å ´åˆã‚‚ã‚ã‚Šã¾ã™ã€‚
- ç”»åƒæ‰€è¦‹: èƒ¸éƒ¨Xç·šã€CTã€MRIãªã©ã®ä¸»è¦ãªæ‰€è¦‹ã‚’è¨˜è¿°ã—ã¾ã™ã€‚
Figureã¨ã—ã¦æç¤ºã™ã‚‹ç”»åƒã«ã¤ã„ã¦ã¯ã€ãã®èª¬æ˜ã‚’ã“ã“ã«è¨˜è¿°ã—ã¾ã™ã€‚
- ç—…ç†æ‰€è¦‹: ç”Ÿæ¤œãªã©ã‚’è¡Œã£ãŸå ´åˆã¯ã€ãã®çµ„ç¹”å­¦çš„æ‰€è¦‹ã‚’è¨˜è¿°ã—ã¾ã™ã€‚

#### æ‰‹é †3: å…¥é™¢å¾ŒçµŒéã¨æ²»ç™‚

- è¨ºæ–­ã«è‡³ã‚‹ã¾ã§ã®æ€è€ƒãƒ—ãƒ­ã‚»ã‚¹ï¼ˆé‘‘åˆ¥è¨ºæ–­ï¼‰ã¨ã€ãã‚Œã‚’è£ä»˜ã‘ã‚‹è¿½åŠ æ¤œæŸ»ã®çµæœã‚’è¨˜è¿°ã—ã¾ã™ã€‚
- æœ€çµ‚çš„ãªè¨ºæ–­åã‚’è¿°ã¹ã¾ã™ã€‚
- è¡Œã£ãŸæ²»ç™‚ï¼ˆè–¬å‰¤åã€æŠ•ä¸é‡ã€æŠ•ä¸æœŸé–“ï¼‰ã¨ã€ãã‚Œã«å¯¾ã™ã‚‹æ‚£è€…ã®åå¿œï¼ˆç—‡çŠ¶ã€æ¤œæŸ»ãƒ‡ãƒ¼ã‚¿ã€ç”»åƒæ‰€è¦‹ã®å¤‰åŒ–ï¼‰ã‚’æ™‚ç³»åˆ—ã«æ²¿ã£ã¦è¨˜è¿°ã—ã¾ã™ã€‚
Figure 2ã§ä½œæˆã—ãŸã‚ˆã†ãªçµŒéã‚°ãƒ©ãƒ•ãŒã€ã“ã®éƒ¨åˆ†ã®ç†è§£ã‚’å¤§ã„ã«åŠ©ã‘ã¾ã™ã€‚

#### æ‰‹é †4: è»¢å¸°ã¨é€€é™¢å¾ŒçµŒé

- æœ€çµ‚çš„ãªæ‚£è€…ã®è»¢å¸°ï¼ˆå¯›è§£ã€è»½å¿«ã€æ­»äº¡ãªã©ï¼‰ã‚’è¨˜è¿°ã—ã¾ã™ã€‚
- é€€é™¢å¾Œã®å¤–æ¥ã§ã®çµŒéã‚„ã€æ²»ç™‚ã®æ¼¸æ¸›ãƒ»ä¸­æ­¢ã«ã¤ã„ã¦ã‚‚è§¦ã‚Œã¾ã™ã€‚

### ğŸ¤– æ¨å¥¨AIãƒ„ãƒ¼ãƒ«

| ãƒ„ãƒ¼ãƒ« | ç”¨é€” | å„ªå…ˆåº¦ |
|---|---|---|
| ChatGPT / Claude | Step 5ã§ä½œæˆã—ãŸã‚µãƒãƒªãƒ¼ã‹ã‚‰ã€ç—‡ä¾‹æç¤ºã®æ–‡ç« ã‚’ç”Ÿæˆã™ã‚‹ã€‚æ–‡ç« ã®æ™‚åˆ¶ï¼ˆéå»å½¢ï¼‰ã‚„å®¢è¦³æ€§ã‚’ãƒã‚§ãƒƒã‚¯ã™ã‚‹ã€‚ | â­â­â­â­ |

### ğŸ’¡ ãƒ—ãƒ­ãƒ³ãƒ—ãƒˆé›†

#### ãƒ—ãƒ­ãƒ³ãƒ—ãƒˆ1: ç—‡ä¾‹ã‚µãƒãƒªãƒ¼ã‹ã‚‰ç—‡ä¾‹æç¤ºã®æ–‡ç« ã‚’ç”Ÿæˆã™ã‚‹

```
# æŒ‡ç¤º
ã‚ãªãŸã¯ãƒ¡ãƒ‡ã‚£ã‚«ãƒ«ãƒ©ã‚¤ã‚¿ãƒ¼ã§ã™ã€‚ä»¥ä¸‹ã®ç—‡ä¾‹ã‚µãƒãƒªãƒ¼ï¼ˆç®‡æ¡æ›¸ãï¼‰ã‚’åŸºã«ã€åŒ»å­¦è«–æ–‡ã®ã€Œç—‡ä¾‹æç¤ºï¼ˆCase Presentationï¼‰ã€ã‚»ã‚¯ã‚·ãƒ§ãƒ³ã®æ–‡ç« ã‚’ã€éå»å½¢ã§ã€å®¢è¦³çš„ãªäº‹å®Ÿã®ã¿ã‚’è¨˜è¿°ã™ã‚‹ã‚¹ã‚¿ã‚¤ãƒ«ã§ä½œæˆã—ã¦ãã ã•ã„ã€‚

# ç—‡ä¾‹ã‚µãƒãƒªãƒ¼
- 45æ­³ç”·æ€§
- ä¸»è¨´: ä¹¾æ€§å’³å—½ã€åŠ´ä½œæ™‚å‘¼å¸å›°é›£ï¼ˆ2é€±é–“å‰ã‹ã‚‰ï¼‰
- æ—¢å¾€æ­´: ç‰¹è¨˜äº‹é …ãªã—
- ç”Ÿæ´»æ­´: å–«ç…™æ­´ãªã—
- å…¥é™¢æ™‚æ‰€è¦‹: SpO2 95% (room air), ä¸¡å´è‚ºé‡ã«fine cracklesè´å–
- è¡€æ¶²æ¤œæŸ»: WBC 11,000/Î¼L, CRP 8.5 mg/dL, KL-6 1,200 U/mL
- èƒ¸éƒ¨CT: ä¸¡å´è‚ºã«ã‚³ãƒ³ã‚½ãƒªãƒ‡ãƒ¼ã‚·ãƒ§ãƒ³ã¨ã™ã‚Šã‚¬ãƒ©ã‚¹å½±
- è¨ºæ–­: æ°—ç®¡æ”¯è‚ºèƒæ´—æµ„(BAL)ã¨çµŒæ°—ç®¡æ”¯è‚ºç”Ÿæ¤œ(TBLB)ã®çµæœã€å™¨è³ªåŒ–è‚ºç‚(OP)ã¨è¨ºæ–­
- æ²»ç™‚ã¨çµŒé: 
  - ãƒ—ãƒ¬ãƒ‰ãƒ‹ã‚¾ãƒ­ãƒ³(PSL) 30mg/æ—¥ã‚’é–‹å§‹
  - æ²»ç™‚é–‹å§‹å¾Œ2é€±é–“ã€ç—‡çŠ¶ã¨ç”»åƒæ‰€è¦‹ãŒæ‚ªåŒ–
  - ã‚¹ãƒ†ãƒ­ã‚¤ãƒ‰æŠµæŠ—æ€§ã¨åˆ¤æ–­ã—ã€ã‚·ã‚¯ãƒ­ãƒ›ã‚¹ãƒ•ã‚¡ãƒŸãƒ‰é–“æ¬ ç™‚æ³•(IVCY) 1000mg/æœˆã‚’è¿½åŠ 
  - IVCYé–‹å§‹å¾Œã€é€Ÿã‚„ã‹ã«ç—‡çŠ¶ã€æ¤œæŸ»æ‰€è¦‹ã€ç”»åƒæ‰€è¦‹ãŒæ”¹å–„
- è»¢å¸°: PSLæ¼¸æ¸›ã—ã€IVCYã‚’6ã‚µã‚¤ã‚¯ãƒ«æ–½è¡Œå¾Œã€å¯›è§£çŠ¶æ…‹ã§æ²»ç™‚çµ‚äº†ã€‚å†ç™ºãªãå¤–æ¥çµŒéè¦³å¯Ÿä¸­ã€‚

# åˆ¶ç´„
- å…¨ä½“ã‚’3ã€œ4ãƒ‘ãƒ©ã‚°ãƒ©ãƒ•ã§æ§‹æˆã™ã‚‹ã“ã¨
- å°‚é–€çš„ã§ç°¡æ½”ãªåŒ»å­¦è‹±èªã§è¨˜è¿°ã™ã‚‹ã“ã¨
```

æ´»ç”¨ä¾‹: ã“ã®ãƒ—ãƒ­ãƒ³ãƒ—ãƒˆã¯ã€ãƒ‡ãƒ¼ã‚¿æ•´ç†ã‹ã‚‰å®Ÿéš›ã®åŸ·ç­†ã¸ã®æ©‹æ¸¡ã—ã‚’è‡ªå‹•åŒ–ã—ã¾ã™ã€‚
ç”Ÿæˆã•ã‚ŒãŸæ–‡ç« ã‚’åŸºã«ã€è©³ç´°ãªæ•°å€¤ã‚’è¿½è¨˜ã—ãŸã‚Šã€è¡¨ç¾ã‚’èª¿æ•´ã—ãŸã‚Šã™ã‚‹ã“ã¨ã§ã€åŠ¹ç‡çš„ã«åŸ·ç­†ã‚’é€²ã‚ã‚‰ã‚Œã¾ã™ã€‚

### ğŸ“š å®Ÿè·µä¾‹

ä¸Šè¨˜ãƒ—ãƒ­ãƒ³ãƒ—ãƒˆã§ç”Ÿæˆã•ã‚ŒãŸè‹±æ–‡ã‚’åŸºã«ã€ä»¥ä¸‹ã®ã‚ˆã†ãªç—‡ä¾‹æç¤ºã‚’ä½œæˆã€‚

> A 45-year-old man with no significant medical history was admitted for a 2-week history of non-productive cough and exertional dyspnea. He was a never-smoker. On admission, his oxygen saturation was 95% on room air, and fine crackles were audible over bilateral lung fields. Laboratory tests revealed a white blood cell count of 11,000/Î¼L, C-reactive protein of 8.5 mg/dL (normal <0.3), and Krebs von den Lungen-6 (KL-6) of 1,200 U/mL (normal <500). A chest computed tomography (CT) scan showed bilateral patchy consolidations and ground-glass opacities (Figure 1A).
> 
> Based on the findings of bronchoalveolar lavage and transbronchial lung biopsy, he was diagnosed with OP. Treatment was initiated with prednisolone (PSL) at a dose of 30 mg/day. However, his symptoms and radiological findings worsened over the following two weeks (Figure 1B). Given the resistance to corticosteroid therapy, intermittent intravenous cyclophosphamide (IVCY) at a dose of 1000 mg/month was added. Following the initiation of IVCY, his symptoms, laboratory data, and radiological abnormalities improved dramatically (Figure 1C, Figure 2). After six cycles of IVCY and tapering of PSL, he achieved remission and has remained disease-free during outpatient follow-up.

### âš ï¸ ã‚ˆãã‚ã‚‹å¤±æ•—ã¨å¯¾å‡¦æ³•

- å¤±æ•—: ç—‡ä¾‹æç¤ºã«ã€è‡ªåˆ†ã®è§£é‡ˆã‚„è€ƒå¯Ÿã‚’æ›¸ã„ã¦ã—ã¾ã†ï¼ˆä¾‹: ã€Œã“ã®æ‰€è¦‹ã¯ã€œã‚’ç¤ºå”†ã™ã‚‹ã€ï¼‰ã€‚
  - å¯¾å‡¦æ³•: ç—‡ä¾‹æç¤ºã¯ã€ã‚ãã¾ã§å®¢è¦³çš„ãªäº‹å®Ÿã‚’è¨˜è¿°ã™ã‚‹ã‚»ã‚¯ã‚·ãƒ§ãƒ³ã§ã™ã€‚
è§£é‡ˆã‚„ä»–ã®æ–‡çŒ®ã¨ã®æ¯”è¼ƒã¯ã€ã™ã¹ã¦è€ƒå¯Ÿï¼ˆDiscussionï¼‰ã§è¡Œã„ã¾ã™ã€‚
ã“ã“ã§ã¯ã€Œã€œã§ã‚ã£ãŸã€ã€Œã€œã‚’èªã‚ãŸã€ã¨ã„ã†äº‹å®Ÿã®è¨˜è¿°ã«å¾¹ã—ã¾ã—ã‚‡ã†ã€‚

- å¤±æ•—: ä¸è¦ãªæƒ…å ±ï¼ˆæ­£å¸¸ç¯„å›²ã®æ¤œæŸ»ãƒ‡ãƒ¼ã‚¿ãªã©ï¼‰ã‚’å»¶ã€…ã¨ç¾…åˆ—ã—ã¦ã—ã¾ã†ã€‚
  - å¯¾å‡¦æ³•: èª­è€…ãŒçŸ¥ã‚ŠãŸã„ã®ã¯ã€è¨ºæ–­ã‚„æ²»ç™‚çµŒéã®ç†è§£ã«ä¸å¯æ¬ ãªæƒ…å ±ã§ã™ã€‚
ã‚¹ãƒˆãƒ¼ãƒªãƒ¼ã«é–¢ä¿‚ã®ãªã„ãƒ‡ãƒ¼ã‚¿ã¯ã€æ€ã„åˆ‡ã£ã¦çœç•¥ã™ã‚‹ã‹ã€ã€ŒOther laboratory data were within normal limits.ã€ã®ã‚ˆã†ã«è¦ç´„ã—ã¾ã—ã‚‡ã†ã€‚

### ğŸ’ª ä¸Šç´šè€…å‘ã‘TIPS

åŸ·ç­†å¾Œã€CAREã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ã®ãƒã‚§ãƒƒã‚¯ãƒªã‚¹ãƒˆã‚’ç‰‡æ‰‹ã«ã€è‡ªåˆ†ã®æ›¸ã„ãŸç—‡ä¾‹æç¤ºã‚’ã‚»ãƒ«ãƒ•ãƒã‚§ãƒƒã‚¯ã—ã¦ã¿ã¾ã—ã‚‡ã†ã€‚
å„é …ç›®ãŒé©åˆ‡ã«è¨˜è¿°ã•ã‚Œã¦ã„ã‚‹ã‹ã‚’ç¢ºèªã™ã‚‹ã“ã¨ã§ã€å›½éš›æ¨™æº–ã«æº–æ‹ ã—ãŸã€è³ªã®é«˜ã„ç—‡ä¾‹å ±å‘Šã«è¿‘ã¥ãã¾ã™ã€‚

### âœ… ãƒã‚§ãƒƒã‚¯ãƒªã‚¹ãƒˆ

- [ ] ç—‡ä¾‹æç¤ºã¯ã€å®¢è¦³çš„ãªäº‹å®Ÿã®ã¿ã§æ§‹æˆã•ã‚Œã¦ã„ã‚‹ã‹ï¼Ÿï¼ˆè§£é‡ˆã‚„è€ƒå¯Ÿã¯å«ã¾ã‚Œã¦ã„ãªã„ã‹ï¼Ÿï¼‰
- [ ] æ™‚é–“çµŒéã«æ²¿ã£ã¦ã€è«–ç†çš„ã«è¨˜è¿°ã•ã‚Œã¦ã„ã‚‹ã‹ï¼Ÿ
- [ ] è–¬å‰¤åï¼ˆä¸€èˆ¬åï¼‰ã€æŠ•ä¸é‡ã€å˜ä½ã¯æ­£ç¢ºã«è¨˜è¼‰ã•ã‚Œã¦ã„ã‚‹ã‹ï¼Ÿ
- [ ] CAREã‚¬ã‚¤ãƒ‰ãƒ©ã‚¤ãƒ³ã®é …ç›®ã‚’ç¶²ç¾…ã§ãã¦ã„ã‚‹ã‹ï¼Ÿ

